Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Titel:
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Auteur:
Li, Bob T Meric-Bernstam, Funda Bardia, Aditya Naito, Yoichi Siena, Salvatore Aftimos, Philippe Anderson, Ian Curigliano, Giuseppe de Miguel, Maria Kalra, Maitri Oh, Do-Youn Park, Joon Oh Postel-Vinay, Sophie Rha, Sun Young Satoh, Taroh Spanggaard, Iben Michelini, Flavia Smith, Ann Machado, Karime Kalil Saura, Cristina